MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Understanding Social Isolation before, during and after the Covid-19 pandemic among Patients with Parkinson’s disease

    A. Mehta, S. Ng, N. Chia, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan (Singapore, Singapore)

    Objective: The aim of this study was to understand and measure the effect of social network support in patients with Parkinson’s disease(PwP) before, during and…
  • 2023 International Congress

    Neurogenic Orthostatic Hypotension in Parkinson’s Disease: Is there a role for Locus Coeruleus Magnetic Resonance Imaging?

    G. Palermo, G. Bellini, A. Galgani, F. Lombardo, N. Martini, R. Morganti, D. Paoli, S. de Cori, FS. Giorgi, R. Ceravolo (Pisa, Italy)

    Objective: To test whether degeneration of the Locus Coeruleus (LC) is associated with Orthostatic Hypotension (OH) in Parkinson’s disease (PD).To test whether degeneration of the…
  • 2023 International Congress

    How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial

    R. Hauser, G. Banisadr, S. Fisher, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…
  • 2023 International Congress

    Novel digital marker detects minor hallucinations online at home of patients with Parkinson’s disease

    L. Albert, F. Bernasconi, J. Potheegadoo, B. Herbelin, O. Blanke (Geneva, Switzerland)

    Objective: The aim is to develop a novel implicit and quantitative marker for minor hallucinations (MH) in Parkinson’s disease (PD) for a better tracking of…
  • 2023 International Congress

    Are GBA–Parkinson Disease patients’ good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort

    M. Avenali, R. Zangaglia, G. Cuconato, I. Palmieri, A. Albanese, CA. Artusi, M. Bozzali, F. Cavallieri, R. Cilia, A. Cocco, R. Eleopra, A. Imarisio, G. Imbalzano, C. Ledda, L. Lopiano, M. Malaguti, F. Mameli, P. Mitrotti, F. Spagnolo, C. Tassorelli, F. Valentino, F. Valzania, A. Di Fonzo, C. Pacchetti, EM. Valente (Pavia, Italy)

    Objective: To investigate the impact of GBA variants on the long-term outcome of deep brain stimulation (DBS) in a large cohort of Italian PD subjects…
  • 2023 International Congress

    Does fatigue in Parkinson’s disease impact one’s physical function in daily live?

    B. Lindholm, E. Franzen (Malmö, Sweden)

    Objective: To investigate fatigue at baseline and 3.5 years later and its association with balance and gait over time. Background: In Parkinson’s disease (PD), fatigue…
  • 2023 International Congress

    Does beta band activity correlate with electrode location within the STN in postoperative processed images?

    M. Ruiz-Lopez, B. Tijero, T. Fernandez, G. Bilbao, JC. Gomez-Esteban, E. Ruiz Degopegui (Bilbao, Spain)

    Objective: To identify the best tool for guidance in an initial programming of deep brain stimulation (DBS).To explore the potential correlation between postoperative images created…
  • 2023 International Congress

    Pilot study of outpatient rehabilitation of patients with Huntington’s disease in Russia

    E. Lysogorskaia, T. Ivanov, M. Gukovskaya, A. Mendalieva, L. Brylev (Moscow, Russian Federation)

    Objective: The benefits of exercises and physical activity in Huntington's disease in terms of motor function, gait speed, and balance, as well as a range…
  • 2023 International Congress

    Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration

    C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso (Móstoles, Spain)

    Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…
  • 2023 International Congress

    MDS-UPDRS III Off Severity Level changes as a marker of DBS response

    S. Castillo-Torres, I. Cruz, M. Rossi, M. Wilken, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

    Objective: To determine the change in MDS-UPDRS III severity level after Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) in patients with Parkinson’s disease (PD) and evaluate…
  • « Previous Page
  • 1
  • …
  • 271
  • 272
  • 273
  • 274
  • 275
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley